Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies

Community-acquired bacterial pneumonia (CABP) is one of the leading causes of morbidity and mortality in India and worldwide. Evidence indicates that Gram-positive, Gram-negative, and atypical bacteria are encountered with near-equal frequency. Despite guideline recommendations and antibiotic option...

Full description

Saved in:
Bibliographic Details
Published inLung India Vol. 36; no. 6; pp. 525 - 533
Main Authors Nayar, Sandeep, Hasan, Ashfaq, Waghray, Pradyut, Ramananthan, Srinivasan, Ahdal, Jaishid, Jain, Rishi
Format Journal Article
LanguageEnglish
Published Mumbai Wolters Kluwer India Pvt. Ltd 01.11.2019
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
adult
Adults
Antibacterial agents
antibiotic
Antibiotics
Bacteria
Bacterial infections
community acquired bacterial pneumonia
Doripenem
Failure
Imipenem
Meropenem
Methicillin
Microbial drug resistance
Morbidity
Mortality
Novels
Pathogens
Penicillin
Pneumonia
Proteins
resistance
Review
Staphylococcus infections
Streptococcus infections
Sulbactam
Tazobactam
Ticarcillin
India
United States > US
antibiotic
Adult
bacteria
community acquired bacterial pneumonia
resistance
Online AccessGet full text

Cover

More Information
Summary:Community-acquired bacterial pneumonia (CABP) is one of the leading causes of morbidity and mortality in India and worldwide. Evidence indicates that Gram-positive, Gram-negative, and atypical bacteria are encountered with near-equal frequency. Despite guideline recommendations and antibiotic options for the management of CABP, burden of morbidity and mortality is high, which is attributable to a variety of factors. Failure of empirical therapy, probably because of insufficient microbial coverage, increasing bacterial resistance, and adverse effects of existing treatments, underlies the unsuccessful treatment of CABP, especially in India. Multiple novel therapies that have entered clinical development phases have potential to address some of these issues. This article discusses the current treatment guidelines in CABP, management limitations, and emerging potential treatment options in the management of CABP.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_38_19